Losartan Potassium Tablet, Film Coated
Product Images NDC 71335-0262

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71335-0262). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713350262)

Label for Losartan Potassium 50 mg film-coated tablets by Bryant Ranch Prepack. The label includes drug identification, lot number 1523487, and states it is a white round tablet with 112 count. It compares to Cozaar 50 mg tablet by Zhejiang Huahai Pharma Co Ltd. Storage instructions and warnings to keep out of reach of children are included along with an NDC of 71335-0262.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical structure of losartan potassium, showing the molecular framework including chlorine, hydroxymethyl, and potassium ion components as part of the losartan potassium molecule.*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A line graph comparing the percentage of patients with a primary endpoint over time (up to 66 study months) between Losartan Potassium and Atenolol. Losartan Potassium is represented by a solid line and Atenolol by a dotted line. The graph shows adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over time (in study months) for Atenolol and Losartan Potassium. The graph shows adjusted risk reduction statistics, indicating the efficacy difference between the two treatments over approximately 66 months.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A figure titled 'Primary Endpoint Events within Demographic Subgroups' displaying two side-by-side forest plots. The left plot shows hazard ratios for the primary composite endpoint comparing Losartan Potassium and Atenolol across subgroups such as age, gender, race, ISH, diabetes, and history of CVD. The right plot shows hazard ratios for stroke (fatal and non-fatal) across the same subgroups. Event rates (%) for each treatment group and 95% confidence intervals are plotted, with symbols proportional to sample size. The horizontal axis spans from 0.3 to 3, with direction indicating favor toward Losartan Potassium or Atenolol.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and placebo groups. The x-axis represents months, and the y-axis shows the percentage of patients with the event. The graph indicates a 16.1% risk reduction for Losartan Potassium relative to placebo with a p-value of 0.022.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.